JP2013540105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013540105A5 JP2013540105A5 JP2013524254A JP2013524254A JP2013540105A5 JP 2013540105 A5 JP2013540105 A5 JP 2013540105A5 JP 2013524254 A JP2013524254 A JP 2013524254A JP 2013524254 A JP2013524254 A JP 2013524254A JP 2013540105 A5 JP2013540105 A5 JP 2013540105A5
- Authority
- JP
- Japan
- Prior art keywords
- hematopoietic stem
- cell population
- cells
- progenitor cells
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 205
- 210000004027 cell Anatomy 0.000 claims description 158
- 239000000203 mixture Substances 0.000 claims description 85
- 238000000034 method Methods 0.000 claims description 84
- 230000014509 gene expression Effects 0.000 claims description 79
- 230000001225 therapeutic effect Effects 0.000 claims description 74
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 239000003795 chemical substances by application Substances 0.000 claims description 53
- 210000000130 stem cell Anatomy 0.000 claims description 51
- 102000007299 Amphiregulin Human genes 0.000 claims description 28
- 108010033760 Amphiregulin Proteins 0.000 claims description 28
- 102000004134 Fos-related antigen 2 Human genes 0.000 claims description 28
- 108090000641 Fos-related antigen 2 Proteins 0.000 claims description 28
- 102100025626 GTP-binding protein GEM Human genes 0.000 claims description 28
- 102000003918 Hyaluronan Synthases Human genes 0.000 claims description 28
- 108090000320 Hyaluronan Synthases Proteins 0.000 claims description 28
- 102100028255 Renin Human genes 0.000 claims description 28
- 108090000783 Renin Proteins 0.000 claims description 28
- 102000005228 Cyclic AMP Response Element Modulator Human genes 0.000 claims description 27
- 108010056281 Cyclic AMP Response Element Modulator Proteins 0.000 claims description 27
- 210000004700 fetal blood Anatomy 0.000 claims description 26
- 210000001185 bone marrow Anatomy 0.000 claims description 24
- 230000001400 myeloablative effect Effects 0.000 claims description 24
- 108010061299 CXCR4 Receptors Proteins 0.000 claims description 21
- 102000012000 CXCR4 Receptors Human genes 0.000 claims description 21
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 18
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 18
- 210000005259 peripheral blood Anatomy 0.000 claims description 18
- 239000011886 peripheral blood Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 15
- 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 claims description 14
- 101710116158 GTP-binding protein GEM Proteins 0.000 claims description 14
- 101001057621 Homo sapiens Dual specificity protein phosphatase 4 Proteins 0.000 claims description 14
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims description 14
- 108010008370 protein phosphatase 4 Proteins 0.000 claims description 14
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 12
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 12
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 12
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 12
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 12
- 238000002512 chemotherapy Methods 0.000 claims description 12
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 12
- 238000001959 radiotherapy Methods 0.000 claims description 12
- 101150026563 NR4A2 gene Proteins 0.000 claims description 11
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 10
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 9
- 108020004017 nuclear receptors Proteins 0.000 claims description 9
- 102000006255 nuclear receptors Human genes 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 claims description 8
- 239000003623 enhancer Substances 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010010356 Congenital anomaly Diseases 0.000 claims description 6
- 208000035366 Familial hemophagocytic lymphohistiocytosis Diseases 0.000 claims description 6
- 206010016717 Fistula Diseases 0.000 claims description 6
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims description 6
- 208000017604 Hodgkin disease Diseases 0.000 claims description 6
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 206010028561 Myeloid metaplasia Diseases 0.000 claims description 6
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010055006 Pancreatic sarcoma Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000009527 Refractory anemia Diseases 0.000 claims description 6
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 208000022806 beta-thalassemia major Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000002449 erythroblastic effect Effects 0.000 claims description 6
- 230000003890 fistula Effects 0.000 claims description 6
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002526 pancreas sarcoma Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 208000007056 sickle cell anemia Diseases 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 206010043554 thrombocytopenia Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 101150066398 CXCR4 gene Proteins 0.000 claims description 5
- 108091006065 Gs proteins Proteins 0.000 claims description 5
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 5
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 5
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 5
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims description 5
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 5
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 5
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 5
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims description 5
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims description 5
- 239000012190 activator Substances 0.000 claims description 5
- 230000001919 adrenal effect Effects 0.000 claims description 5
- 208000007502 anemia Diseases 0.000 claims description 5
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 5
- 230000003394 haemopoietic effect Effects 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 210000004885 white matter Anatomy 0.000 claims description 5
- 208000015178 Hurler syndrome Diseases 0.000 claims description 3
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 claims description 2
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 claims description 2
- 108010065026 HLA-DQB1 antigen Proteins 0.000 claims description 2
- 108010061311 HLA-DRB3 Chains Proteins 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 10
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 10
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 4
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 1
- 201000004939 Fanconi anemia Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 150000003166 prostaglandin E2 derivatives Chemical class 0.000 claims 1
- 238000005406 washing Methods 0.000 description 7
- 239000010437 gem Substances 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 2
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37321210P | 2010-08-12 | 2010-08-12 | |
| US61/373,212 | 2010-08-12 | ||
| PCT/US2011/047657 WO2012021845A2 (en) | 2010-08-12 | 2011-08-12 | Improved hematopoietic stem and progenitor cell therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016124416A Division JP6346917B2 (ja) | 2010-08-12 | 2016-06-23 | 改善された造血幹細胞および前駆細胞療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013540105A JP2013540105A (ja) | 2013-10-31 |
| JP2013540105A5 true JP2013540105A5 (enExample) | 2014-08-21 |
| JP6047489B2 JP6047489B2 (ja) | 2016-12-21 |
Family
ID=45568224
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524254A Expired - Fee Related JP6047489B2 (ja) | 2010-08-12 | 2011-08-12 | 改善された造血幹細胞および前駆細胞療法 |
| JP2016124416A Expired - Fee Related JP6346917B2 (ja) | 2010-08-12 | 2016-06-23 | 改善された造血幹細胞および前駆細胞療法 |
| JP2018031941A Expired - Fee Related JP6574279B2 (ja) | 2010-08-12 | 2018-02-26 | 改善された造血幹細胞および前駆細胞療法 |
| JP2018139536A Withdrawn JP2018184448A (ja) | 2010-08-12 | 2018-07-25 | 改善された造血幹細胞および前駆細胞療法 |
| JP2019197587A Withdrawn JP2020029458A (ja) | 2010-08-12 | 2019-10-30 | 改善された造血幹細胞および前駆細胞療法 |
| JP2021172986A Withdrawn JP2022009404A (ja) | 2010-08-12 | 2021-10-22 | 改善された造血幹細胞および前駆細胞療法 |
| JP2023071598A Pending JP2023109761A (ja) | 2010-08-12 | 2023-04-25 | 改善された造血幹細胞および前駆細胞療法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016124416A Expired - Fee Related JP6346917B2 (ja) | 2010-08-12 | 2016-06-23 | 改善された造血幹細胞および前駆細胞療法 |
| JP2018031941A Expired - Fee Related JP6574279B2 (ja) | 2010-08-12 | 2018-02-26 | 改善された造血幹細胞および前駆細胞療法 |
| JP2018139536A Withdrawn JP2018184448A (ja) | 2010-08-12 | 2018-07-25 | 改善された造血幹細胞および前駆細胞療法 |
| JP2019197587A Withdrawn JP2020029458A (ja) | 2010-08-12 | 2019-10-30 | 改善された造血幹細胞および前駆細胞療法 |
| JP2021172986A Withdrawn JP2022009404A (ja) | 2010-08-12 | 2021-10-22 | 改善された造血幹細胞および前駆細胞療法 |
| JP2023071598A Pending JP2023109761A (ja) | 2010-08-12 | 2023-04-25 | 改善された造血幹細胞および前駆細胞療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20140030232A1 (enExample) |
| EP (2) | EP2603227B1 (enExample) |
| JP (7) | JP6047489B2 (enExample) |
| CN (5) | CN103167876B (enExample) |
| AU (1) | AU2011289245B2 (enExample) |
| BR (1) | BR112013003366A2 (enExample) |
| CA (1) | CA2807944C (enExample) |
| ES (1) | ES2654994T3 (enExample) |
| WO (1) | WO2012021845A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103167876B (zh) * | 2010-08-12 | 2016-08-31 | 菲特治疗公司 | 改进的造血干细胞和祖细胞疗法 |
| CN104066837B (zh) | 2011-12-02 | 2020-12-08 | 菲特治疗公司 | 增强的干细胞组合物 |
| EP2785350B1 (en) | 2011-12-02 | 2018-05-02 | Fate Therapeutics, Inc. | Improved methods of treating ischemia |
| WO2014078617A1 (en) * | 2012-11-16 | 2014-05-22 | Albert Einstein College Of Medicine Of Yeshiva University | Identification and use of new tumor-promoting gene in hematological malignancies |
| CN105121632B (zh) * | 2013-02-18 | 2021-08-10 | 大学健康网络 | 由多能干细胞生成肝细胞和胆管细胞的方法 |
| EP2970881A4 (en) * | 2013-03-14 | 2017-01-25 | Children's Medical Center Corporation | Compositions and methods for reprogramming hematopoietic stem cell lineages |
| US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| CN105408472A (zh) | 2013-03-15 | 2016-03-16 | 马卡斯凯尔·托莱夫·拉尔森 | 用于脐带血收集及细胞分离的细胞、方法和装置 |
| US10851412B2 (en) | 2013-03-15 | 2020-12-01 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| RU2525143C1 (ru) * | 2013-03-22 | 2014-08-10 | Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации-Институт медико-биологических проблем Российской академии наук | СПОСОБ ЭКСПАНСИИ МОНОНУКЛЕАРНЫХ КЛЕТОК ПУПОВИННОЙ КРОВИ (пкМНК) ex vivo В ПРИСУТСТВИИ МУЛЬТИПОТЕНТНЫХ СТРОМАЛЬНЫХ МЕЗЕНХИМАЛЬНЫХ КЛЕТОК (ММСК) |
| WO2015077691A2 (en) * | 2013-11-22 | 2015-05-28 | Washington University | Biomarkers for multiple myeloma |
| US11278572B2 (en) | 2014-07-18 | 2022-03-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells |
| CA2974903A1 (en) * | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| US10626372B1 (en) | 2015-01-26 | 2020-04-21 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| HK1256681A1 (zh) * | 2015-04-06 | 2019-10-04 | President And Fellows Of Harvard College | 用於非清髓性预处理的组合物和方法 |
| CN108350419A (zh) * | 2015-07-20 | 2018-07-31 | 安吉克莱茵生物科学有限公司 | 干细胞移植方法和干细胞移植组合物 |
| BR112018001232A2 (pt) | 2015-07-21 | 2018-09-25 | The Children's Medical Center Corporation | pd-l1 que expressa células-tronco hematopoéticas e usos |
| CN122146606A (zh) | 2015-11-04 | 2026-06-05 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| US12642852B1 (en) | 2015-11-04 | 2026-06-02 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| WO2017136837A1 (en) * | 2016-02-06 | 2017-08-10 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
| RU2628092C1 (ru) * | 2016-02-10 | 2017-08-14 | Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ - ИМБП РАН) | Способ получения МСК-ассоциированных недифференцированных гемопоэтических клеток-предшественников с фенотипов CD34+/CD133+ |
| CN105779386B (zh) * | 2016-04-06 | 2019-09-20 | 南京大学 | 一种间充质干细胞在制备治疗m5型白血病药物中的应用 |
| CN105886457A (zh) * | 2016-05-16 | 2016-08-24 | 中国人民解放军军事医学科学院野战输血研究所 | 诱导干细胞分化成外胚层祖细胞的方法 |
| US11542473B2 (en) | 2016-10-21 | 2023-01-03 | Amniotics Ab | Methods and compositions for generating hematopoietic cells |
| CN106754726A (zh) * | 2016-12-28 | 2017-05-31 | 溯源生命科技股份有限公司 | 一种提高人间充质干细胞移植和归巢效率的基因治疗方法 |
| WO2018170046A1 (en) * | 2017-03-14 | 2018-09-20 | Orig3N, Inc. | Hla-indexed repository of ipscs and ipsc-derived stem cells, and related systems and methods |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| EP3647413A1 (en) * | 2018-10-31 | 2020-05-06 | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) | Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation |
| JP2022533191A (ja) * | 2019-05-17 | 2022-07-21 | デヴェラ セラピューティクス インコーポレイテッド | 拡大した幹細胞生成物を使用して、血液悪性腫瘍を有する患者の処置転帰を改善するための組成物および方法 |
| US20220305057A1 (en) * | 2019-06-06 | 2022-09-29 | Medeor Therapeutics, Inc. | Methods of making cellular products by post- mortem mobilization and harvesting of hematopoietic cells |
| WO2020256628A1 (en) | 2019-06-20 | 2020-12-24 | Amniotics Ab | An apparatus for filtering amniotic fluid |
| CN110585432B (zh) * | 2019-08-27 | 2021-10-15 | 中国人民解放军第二军医大学 | 成纤维细胞生长因子受体1在制备防治肠道病毒71型感染药物中的应用 |
| JP7714535B2 (ja) | 2019-10-18 | 2025-07-29 | アムニオティクス・アーベー | 羊水およびそれに由来する細胞から羊水間葉系幹細胞を得るためのプロセスならびに装置 |
| WO2021097346A1 (en) * | 2019-11-14 | 2021-05-20 | Amgen Inc. | Hematopoietic precursor cell production |
| CN114246948A (zh) * | 2020-09-24 | 2022-03-29 | 广州辑因医疗科技有限公司 | 化合物用于提高人造血干细胞移植效率的用途 |
| CN116568802A (zh) * | 2020-10-30 | 2023-08-08 | 西湖生物医药科技(上海)有限公司 | 制备成熟红细胞的体外方法 |
| US12435308B2 (en) | 2020-11-06 | 2025-10-07 | Amniotics Ab | Immunomodulation by amniotic fluid mesenchymal stem cells |
| WO2024040061A2 (en) * | 2022-08-16 | 2024-02-22 | The Regents Of The University Of California | Alleviating graft versus host disease using engineered inkt cells |
| WO2024186146A1 (ko) * | 2023-03-07 | 2024-09-12 | 인제대학교 산학협력단 | 조혈 줄기세포 증식 또는 가동화 촉진용 조성물 및 가동화 조혈 줄기세포 수집방법 |
| WO2026079443A1 (ja) * | 2024-10-09 | 2026-04-16 | 国立大学法人 東京大学 | Ｃｘｃｒ４陽性造血幹細胞の誘導または製造方法および前記ｃｘｃｒ４陽性造血幹細胞を含む細胞集団 |
| CN122128240B (zh) * | 2026-04-30 | 2026-07-31 | 浙江大学医学院附属第一医院(浙江省第一医院) | Jsh-23在人循环造血干/祖细胞的扩增和/或功能增强中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US5709472A (en) * | 1995-10-23 | 1998-01-20 | Lifelines Technology, Inc. | Time-temperature indicator device and method of manufacture |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| US5945337A (en) | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
| JP2001521753A (ja) | 1997-10-31 | 2001-11-13 | アフィメトリックス インコーポレイテッド | 成人臓器及び胎児臓器中の発現プロフィール |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| HK1048302A1 (zh) | 1999-08-13 | 2003-03-28 | 大正制药株式会社 | 前列腺素衍生物 |
| ATE327751T1 (de) | 2000-01-31 | 2006-06-15 | Pfizer Prod Inc | Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| FR2825261B1 (fr) | 2001-06-01 | 2003-09-12 | Maco Pharma Sa | Ligne de prelevement du sang placentaire comprenant une poche de rincage |
| EP1499637A1 (en) * | 2002-04-26 | 2005-01-26 | Kirin Beer Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same |
| US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| US20050176140A1 (en) * | 2004-02-10 | 2005-08-11 | Benedict Daniel J. | Method and apparatus for cell culture using a two liquid phase bioreactor |
| US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
| WO2006047476A2 (en) | 2004-10-26 | 2006-05-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| DE102005062741A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorene und Carbazole als Liganden des EP2 Rezeptors |
| EP1999255A2 (en) * | 2006-03-24 | 2008-12-10 | The Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
| CN101517070A (zh) * | 2006-05-31 | 2009-08-26 | Styx有限责任公司 | 选择干细胞的方法及其用途 |
| CN101506353A (zh) * | 2006-06-15 | 2009-08-12 | 尼奥斯泰姆公司 | 外周造血干细胞的处理方法 |
| US20110165128A1 (en) * | 2008-03-07 | 2011-07-07 | Columbia University In The City Of New York | Homing in mesenchymal stem cells |
| EP3031907B1 (en) * | 2008-11-06 | 2021-01-06 | Indiana University Research and Technology Corporation | Materials and methods to enhance hematopoietic stem cells engraftment procedures |
| BRPI0920976A2 (pt) * | 2008-12-03 | 2015-08-18 | Amorcyte Inc | Composições que melhoram a perfusão da area de infarto e metodos de restauração da lesão vascular. |
| JP2010193879A (ja) * | 2009-01-27 | 2010-09-09 | Jms Co Ltd | 臍帯血造血幹細胞の増殖制御方法およびその用途 |
| CN103167876B (zh) * | 2010-08-12 | 2016-08-31 | 菲特治疗公司 | 改进的造血干细胞和祖细胞疗法 |
-
2011
- 2011-08-12 CN CN201180049420.3A patent/CN103167876B/zh not_active Expired - Fee Related
- 2011-08-12 AU AU2011289245A patent/AU2011289245B2/en not_active Ceased
- 2011-08-12 CN CN201610635871.XA patent/CN106244547B/zh not_active Expired - Fee Related
- 2011-08-12 CA CA2807944A patent/CA2807944C/en active Active
- 2011-08-12 JP JP2013524254A patent/JP6047489B2/ja not_active Expired - Fee Related
- 2011-08-12 BR BR112013003366-5A patent/BR112013003366A2/pt not_active Application Discontinuation
- 2011-08-12 WO PCT/US2011/047657 patent/WO2012021845A2/en not_active Ceased
- 2011-08-12 EP EP11817137.0A patent/EP2603227B1/en not_active Not-in-force
- 2011-08-12 ES ES11817137.0T patent/ES2654994T3/es active Active
- 2011-08-12 EP EP17188681.5A patent/EP3278808A1/en not_active Withdrawn
- 2011-08-12 CN CN202011443538.1A patent/CN112501118A/zh active Pending
- 2011-08-12 CN CN202011436734.6A patent/CN112516167A/zh active Pending
- 2011-08-12 CN CN201610638252.6A patent/CN106214701B/zh not_active Expired - Fee Related
- 2011-08-12 US US13/816,723 patent/US20140030232A1/en not_active Abandoned
-
2016
- 2016-06-23 JP JP2016124416A patent/JP6346917B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-26 JP JP2018031941A patent/JP6574279B2/ja not_active Expired - Fee Related
- 2018-07-25 JP JP2018139536A patent/JP2018184448A/ja not_active Withdrawn
-
2019
- 2019-10-30 JP JP2019197587A patent/JP2020029458A/ja not_active Withdrawn
-
2020
- 2020-05-11 US US16/872,061 patent/US20200339953A1/en not_active Abandoned
-
2021
- 2021-10-22 JP JP2021172986A patent/JP2022009404A/ja not_active Withdrawn
-
2023
- 2023-04-25 JP JP2023071598A patent/JP2023109761A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018104457A5 (enExample) | ||
| JP6483187B2 (ja) | 増強された幹細胞組成物 | |
| Aggarwal et al. | Hematopoietic stem cells: transcriptional regulation, ex vivo expansion and clinical application | |
| BR112013003366A2 (pt) | terapia aperfeiçoada de células tronco hematopoiéticas e progenitoras | |
| Berglund et al. | Advances in umbilical cord blood cell therapy: the present and the future | |
| EP2300599B1 (en) | Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase | |
| US20190330593A1 (en) | Lilrb2 and notch-mediated expansion of hematopoietic precursor cells | |
| JP2023156522A (ja) | 細胞療法を改善するための方法 | |
| US20250115867A1 (en) | Augmentation of cell therapy efficacy including treatment with alpha, 1,3 fucosyltransferase | |
| JP2018184448A5 (enExample) | ||
| JP2019501956A (ja) | 免疫療法に使用するための組成物 | |
| Tung et al. | Ex vivo expansion of umbilical cord blood for transplantation | |
| TWI410495B (zh) | 新穎之人類ｔ細胞群 | |
| JPH11514879A (ja) | 原始ヒト幹細胞を有するＭｐ１リガンドの使用法 | |
| AU2023221021B2 (en) | Compositions and methods for antigen-specific t cell expansion | |
| Mehta et al. | Engineering cord blood to improve engraftment after cord blood transplant | |
| Epah et al. | Implications of hematopoietic stem cells heterogeneity for gene therapies | |
| US20240390425A1 (en) | Rejuvenated aged hematopoietic stem cells and methods of use | |
| Watts et al. | Hematopoietic stem cell expansion and gene therapy | |
| O’Neill et al. | Skeletal stem/progenitor cells provide the niche for extramedullary hematopoiesis in spleen | |
| JP2021502816A5 (enExample) | ||
| Beksac et al. | Modalities to improve cord blood engraftment | |
| Maalaoui | Characterization of the UM171-Graft: Dissecting the lymphoid lineage potential of the UM171-Graft | |
| US20250332260A1 (en) | Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations | |
| US20240400992A1 (en) | Compositions and methods for antigen-specific t cell expansion |